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Introduction: Kaplan-Meier (KM) has become the most used method to evaluate time-to-event
analysis, although it is unsuitable in competing event situations such as death and shock reversal.
Despite that the use of this methodology is not widely disseminated, cumulative incidence analysis
(CIA) is more appropriate in these situations. We used CIA and KM (with 2 different techniques of
censoring) to compare shock reversal in a cohort of patients with septic shock after steroid therapy.
Furthermore, we have analyzed shock reversal in responders and nonresponders to high-dose cortrosyn
test (250 μg).
Methods: Analysis of shock reversal in a cohort of 74 patients with septic shock at a university hospital
was done.
Results: Shock reversal by the 28th day was estimated to be 88% and 72% by KM methods and 59% by
CIA. In nonresponders to cortrosyn test (Δ ≤9 μg/dL), shock reversal was estimated in 80% and 56%
according to KM and 47% according to CIA. As for responders to cortrosyn test, shock reversal was
estimated in 90% and 77% according to KM and 64% according to the CIA method.
Conclusion: Kaplan-Meier overestimates shock reversal. Cumulative incidence analysis seems to be a
more appropriate method to analyze shock reversal. Future trials intended to analyze shock reversal
should apply CIA.
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In some medical situations, the main outcome is the time
to an event, such as shock reversal in patients with septic
shock. There are many methods to evaluate time-to-event
317.e8 R.B. Moraes et al.data. Instead of “time-to-event,” the word “survival” is
commonly used to designate these methods, although the
words are not synonymous. In common, these techniques
estimate the probability of occurrence of events at every
follow-up period for the population cohort [1,2].
Also known as “product-limit method,” Kaplan-Meier
(KM) has become the most conventional method to assess
time-to-event analysis; besides, it is executable in most
statistical software packages. In the scope of critical care,
some trials have applied this methodology for the purpose of
assessing the influence of steroid therapy in patients with
sepsis and septic shock on shock reversal [3-6]. These trials
and their respective meta-analysis allowed concluding that
steroids decrease vasopressor dependence [7,8].
Shock reversal is currently the only consensual clinical
benefit of steroids in patients with septic shock, mainly in
patients with critical illness–related corticosteroid insuffi-
ciency that can be diagnosed as baseline serum cortisol
concentration less than 10 μg/d or cortisol variation (Δ) 9
μg/dL or less [9]. Although it has been ideally suited to
analyze several time-to-event situations, KM is inadequate to
analyze vasopressor withdrawal because it works with time
set to a single type of event; thus, assuming independence
between event and censoring. This assumption is not
confirmed when analyzing shock reversal, as this is a
competing event. Kaplan-Meier method is a “2-state model”
[10]; in this example, at the beginning of the observation, all
patients were in shock, whereas during follow-up, the curve
showed a step-down as the patient exhibited shock reversal
as an outcome. The problem is that some patients will exhibit
the competing event “death” but before the main outcome
(shock reversal) is disclosed during the follow-up period.
Yet, there are different ways to deal with this limitation in
KM techniques. The 2 most common ways are (1) at the
moment the patient dies, he or she is censored, and; (2) the
patients who die in shock during the follow-up are
considered to have been in shock (alive) until the end of
the follow-up period. These corrections induce bias in the
interpretation of curves and may overestimate the incidence
of shock reversal.
In scenarios where there are competing events,
methodologies that correct the probability of 1 event to
the competing event are more accurate and should be
used. These methods bring into question the assumption
the probability of another outcome (death), thereby
correcting the probability of the main outcome regarding
the competing event. One of the terms used in the
literature to designate such methodologies is “cumulative
incidence analysis” (CIA). Unfortunately, researchers have
only recently become aware of the benefits of this
methodology [11].
In this study, both CIA and KM methodologies have been
applied to compare estimates of shock reversal in a cohort of
patients with septic shock after steroid therapy. We have also
analyzed estimates of shock reversal based on the responses
to cortrosyn test.2. Materials and methods
Our study used data from a trial designed to compare low-
and high-dose cortrosyn tests (to be published). The trial
included 74 patients older than 18 years sequentially
submitted to both tests at a medical-surgical intensive care
unit (ICU) of a tertiary university hospital; patients were
prospectively enrolled from November 2006 to February
2009. Patients who were eligible for enrollment into the
study were those who met the criteria of the American
College of Chest Physicians/Society of Critical Care
Medicine Conference Consensus Committee [12] for septic
shock; have systolic blood pressure less than 90 mm Hg,
despite of adequate fluid replacement and use of vasopressor
for at least 1 hour for a period inferior to 96 hours at the ICU;
and were under invasive mechanical ventilation. The
decision concerning low-dose hydrocortisone therapy after
the cortrosyn test and other therapeutic decisions was taken
at the discretion of the patient's physician without influence
of researchers. The following were considered as exclusion
criteria: previous use (short or long term) of cortisol; use of
drugs known to suppress adrenal function, such as etomidate,
spironolactone, oral contraceptives, or antifungals; AIDS;
history of previous adrenal failure; pathology of hypotha-
lamic-pituitary-adrenal axis; pregnancy; and shock due to
other etiologies. All patients were submitted to high-dose
(250 μg) cortrosyn test (tetracosactide, Synacthene;
NOVARTIS, Rueil-Malmaison, France). Serum cortisol
concentration was measured at baseline 30 and 60 minutes
after cortrosyn infusion. Cortisol variation (Δ) was calculated
as the difference between peak serum cortisol concentration
(30 or 60 minutes) and the baseline cortisol concentration
before the cortrosyn test. Patients were considered non-
responders to the high-dose test when Δ cortisol is 9 μg/dL
or less. Because of the overlap of results between responders
and nonresponders to the low- and high-dose cortrosyn tests,
the analysis of the low-dose test was suppressed in this study.
Serum cortisol analysis was performed by chemiluminescence
(Modular E-170; Roche, Vasel, Switzerland).The protocol was
approved by the ethics committee. The following variables
were recorded: age, sex, admission category (medical or
surgical), source of infection, Acute Physiology and Chronic
Health Evaluation (APACHE) II score [13], serum albumin,
and glycemia. Patients were followed up for 28 days. Shock
reversal was defined as systolic blood pressure more than 90
mm Hg without vasopressor support for at least 24 hours.3. Statistical analysis
Statistical analyses were conducted using SPSS 17.0
statistical package software (SPSS Incorporation, Chicago,
Ill). The results of continuous variables are expressed as the
mean ± SD. Shock reversal was estimated by KM and CIA
methods. Cumulative incidence analysis was conducted as
Table 1 Characteristics of patients
Characteristic
Age, y 62 ± 16
Male, % 57
Admission category
Medical, % 53
Surgical, % 47
APACHE 25.7 ± 8.5
Source of infection
Respiratory, % 46
Abdominal, % 42
Others, % 12
Serum albumin, g/dL 2.0 ± 0.5
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compared by Cox proportional hazards to competing
events [15]. Kaplan-Meier method allows different cen-
soring applications. Two different approaches to KM have
been performed. In the first approach (KM1), the
occurrence of death before shock reversal resulted in
censoring in the moment of death. In the second approach
(KM2), the competing event death was ignored, that is,
they were considered to be in shock until the end of the
follow-up period.
Mortality was estimated by the KM method, and results
were compared between groups using the log-rank test.
Furthermore, P b .05 was considered statistically significant.Blood glucose, mg/dL 137 ± 45
Baseline cortisol, μg/dL 31.8 ± 20.3
Δ Cortisol after cortrosyn test, μg/dL
All patients 16.3 ± 10.1
Nonresponders 4.8 ± 2.8
Responders 19.9 ± 9.0
28-day mortality, % 57
Data are presented as mean ± SD.
Table 2 Estimates of shock reversal according to KM
methods with different censoring schemes (KM1 and KM2)
and CIA in the entire cohort according to the response to
cortrosyn test
Shock reversal
KM1 (%) KM2 (%) CIA (%)
All patients 88 72 59
Δ Cortisol ≤9 μg/dL 80 56 47
Δ Cortisol N9 μg/dL 90 77 644. Results
In this cohort of 74 patients, 57% were men. Mean age
was 62 ± 16 years, and APACHE score was 25.7 ± 8.5.
Fifty-three percent were medical ICU admissions, and 47%
were surgical admissions. In 46% of admissions, the source
of infection was respiratory, whereas in 42% the source, it
was abdominal, and in 12%, other sources were observed.
Only 6 patients (8%) have not received hydrocortisone. This
decision was taken at the discretion of the patient's
physician without influence of researchers and was not
related to serum cortisol concentration or response to
cortrosyn test. Analysis performed with exclusion of these 6
patients has not influenced results. Blood glucose was 137 ±
45 mg/dL. Mean serum albumin was 2.0 ± 0.5 g/dL, and
there was no difference between responders or nonre-
sponders to cortrosyn. Baseline cortisol before conduction
of cortrosyn test was 31.8 ± 20.3 μg/dL. In this cohort, 24%
(18/74) of patients were nonresponders to the test. Cortisol
variation is shown in Table 1. The variation was not related
to baseline cortisol.
In the entire cohort, shock reversal was estimated in 88%
of patients when KM1method was used and 72%when KM2
method was adopted. Estimate was only 59% when CIA was
used. Responders to the cortrosyn test had shock reversal
estimated in 90%, according to KM1, 77% according to
KM2, and 64% when analysis was performed with CIA.
Among nonresponders to cortrosyn test, KM1 estimated
shock reversal in 80% and 56% with KM2. The estimate was
47% when CIA was applied (Table 2 and Fig. 1).
Overall mortality on the 28th day was 57%. Mortality in
nonresponders to the cortrosyn test was 61%, whereas in
responders, it was 55% (log-rank P = .39). Table 3 shows the
difference in estimates of shock reversal between both KM
methods used and CIA and its relation to mortality. The
difference is greater when KM1 is applied. In addition, it has
reached 33% among nonresponders to cortrosyn, which was
the group with the highest mortality rate (61%). The
discrepancy between both methods is smaller (9%) when
comparison is conducted between CIA and KM2.5. Discussion
Despite that KM became the most popular method to
assess time-to-event analysis in situations with competing
events, it is no longer considered the most appropriate
method. Our study shows that KM overestimates shock
reversal in scenarios with competing events like death.
The use of stress dose steroids in patients with septic
shock is partially supported by the results of trials that
allowed concluding that steroids increase shock reversal [3-
6]. Kaplan-Meier method has been applied in these trials,
thereby leading to such conclusion. Briegel et al [3] used KM
“ignoring the deaths” method; patients who died using
vasopressor during follow-up were therefore considered to
be alive and using vasopressor during all the follow-up
period; thus, performing an estimative described in our trial
as KM2. This way of censoring is the one that reaches results
closer to those of CIA, but it is an “actuarial” estimated
vasopressor withdrawal, and it actually estimates how many
patients would exhibit shock reversal if no patients had died
during the follow-up. Indeed, the most influent trials
analyzing steroids and shock reversal do not mention how
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Fig. 1 Comparison of time-to-shock reversal between KM
methods with different censoring (KM1 and KM2) and CIA in
the entire cohort and according to the response to cortrosyn test. A,
All patients. B, Δ cortisol 9 μg/dL or less. C, Δ cortisol greater than
9 μg/dL. D, All patients. E, Δ cortisol 9 μg/dL or less. F, Δ cortisol
greater than 9 μg/dL.
Table 3 Comparison of estimate of shock reversal between
CIA and KMmethods with different censoring schemes (KM1
and KM2) and relation to mortality in the entire cohort and
according to the response to cortrosyn test
Shock reversal Mortality (%)
Difference
KM1-CIA (%)
Difference
KM2-CIA (%)
All patients 29 13 57
Δ Cortisol
≤9 μg/dL
33 9 61
Δ Cortisol
N9 μg/dL
26 13 55
317.e10 R.B. Moraes et al.patients were censored. Bollaert et al [4], Annane et al [5],
nor Sprung et al [6] have described how patients were
censored at time of death. The authors were contacted to
inform how they have censored dead patients in every trial. The
authors of CORTICUS (Corticosteroid Therapy of Septic
Shock) [6] have declared that they used the same methods of
censoring of Briegel et al [3]. In Bollaert et al [4], authors have
censored patients in the moment of death the sameway we have
performed inKM1 analysis. Our study shows that this technique
(KM1) is the one thatmost overestimates shock reversal and that
the higher the mortality, the higher is the bias estimated by this
technique. We did not have access to data of Annane et al [5].
Although patients can be censored in different ways [16],
KM is believed to be proper for working with time for a
single type of event. In this technique, the assumption of
independence between event and censoring is pivotal, and it
fails in scenarios with competing events. To correct the
prediction of the number of patients who have actually
exhibited shock reversal, it is necessary to apply a multistate
model, that is, a model that deals with more than a single
event and that does not assume independence between main
and competing events; hence, allowing patients to present 1
event (in this case, shock reversal) without being censored to
a competing event (in this case, death).
These methods are usually designated not only as CIA but
also as expressions such as actual CIA or conditional
probability estimation, which can be found in the medical
literature. Such designations have been used by physicians in
areas where competing events are usual; this can be observed
in cardiac surgery (death competes with valve durability)
[17,18] or oncology (death competes with disease relapse).
Although competing events are common in critical care and
emergency medicine, CIA has surprisingly not been as
frequently applied as it should have been; recommendations
support that this methodology is more appropriate though [19].
6. Conclusion
Steroid therapy in septic shock is partially supported by
the statement that steroids increase shock reversal. The trials
that lead to this conclusion have been applied using the KM
method, and different censoring schemes were therefore used
for this purpose. Our trial exemplifies that, mainly, when
patients are censored in the moment of death, KM
overestimates steroid influence on shock reversal. Cumula-
tive incidence analysis is more accurate in addressing shock
reversal because it addresses the actual risk of shock reversal.
We hence suggest that future trials intended to analyze
competing events, such as shock reversal and death, should
apply CIA instead of KM.
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